Profarma Distribuidora de Produtos Farmaceuticos SA
BOVESPA:PFRM3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Profarma Distribuidora de Produtos Farmaceuticos SA
BOVESPA:PFRM3
|
BR |
|
I
|
Ikigai Ventures Ltd
LSE:IKIV
|
GG |
|
E
|
EssilorLuxottica SA
OTC:ESLOF
|
FR |
|
R1 RCM Inc
NASDAQ:RCM
|
US |
|
LS Electric Co Ltd
KRX:010120
|
KR |
|
S
|
Sasbadi Holdings Bhd
KLSE:SASBADI
|
MY |
|
G
|
Giant Biogene Holding Co Ltd
HKEX:2367
|
CN |
|
Edgewise Therapeutics Inc
NASDAQ:EWTX
|
US |
|
Beijing Trust & Far Technology Co Ltd
SZSE:300231
|
CN |
|
Helios Towers PLC
LSE:HTWS
|
UK |
|
B
|
Balticon SA
WSE:BLT
|
PL |
|
Shopper360 Ltd
SGX:1F0
|
MY |
|
S
|
Sibanye Stillwater Ltd
JSE:SSW
|
ZA |
|
Assure Holdings Corp
OTC:IONM
|
US |
Operating Income
Forecast
For the last 14 years the
compound annual growth rate for
Profarma Distribuidora de Produtos Farmaceuticos SA's operating income is
13%.
The projected
CAGR
for the next 7 years is
-24%.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is PFRM3's stock price target?
Not Available
PFRM3 doesn't have any price targets made by Wall Street professionals.
What is Profarma Distribuidora de Produtos Farmaceuticos SA's Revenue forecast?
Projected CAGR
-13%
For the last 14 years the
compound annual growth rate for
Profarma Distribuidora de Produtos Farmaceuticos SA's revenue is
11%.
The projected
CAGR
for the next 7 years is
-13%.
What is Profarma Distribuidora de Produtos Farmaceuticos SA's Operating Income forecast?
Projected CAGR
-24%
For the last 14 years the
compound annual growth rate for
Profarma Distribuidora de Produtos Farmaceuticos SA's operating income is
13%.
The projected
CAGR
for the next 7 years is
-24%.
